# Surufatinib Combined with Envolizumab As Second-line Treatment for Recurrent/Metastatic HNSCC

> **NCT06876844** · PHASE2 · RECRUITING · sponsor: **Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University** · enrollment: 24 (estimated)

## Conditions studied

- Head and Neck Cancer
- Head and Neck Cancer Squamous Cell Carcinoma

## Interventions

- **DRUG:** combination of Surufatinib and Envolizumab

## Key facts

- **NCT ID:** NCT06876844
- **Lead sponsor:** Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-30
- **Primary completion:** 2027-09-30
- **Final completion:** 2027-09-30
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06876844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06876844, "Surufatinib Combined with Envolizumab As Second-line Treatment for Recurrent/Metastatic HNSCC". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06876844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*